February 13, 2022 /
MS Research Study and Reports
January 20, 2022 04:26 PM Eastern Standard Time
METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes (CTL). Multiple sclerosis is a chronic inflammatory disease of the central nervous system, for which there is currently no definitive cure.
“Recent studies on multiple sclerosis have suggested a probable link between latent infection with EBV and later onset of the inflammation that degrades the myelin sheath and causes multiple sclerosis,” said Neal Flomenberg, M.D., Chairman of Tevogen’s Scientific Advisory Board. “We look to apply our significant expertise in off-the-shelf allogeneic SARS-CoV-2 specific CD8+ cytotoxic T lymphocytes (CTLs) to explore EBV specific CTL therapy as a possible means of addressing the unmet needs of MS patients,” Flomenberg added.
“Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to develop pathways to alleviate the suffering from MS,” said Tevogen CEO Ryan Saadi, M.D., M.P.H. “I’m hopeful that our disruptive T cell technology will eventually offer accessible immunotherapies to millions suffering from viral infections, cancers and other diseases with high unmet need.”
About Tevogen’s Investigational T Cell Therapy for COVID-19
Tevogen’s investigational T cell therapy for COVID-19, TVGN-489, is currently undergoing proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials – Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.
Click to Subscribe for the MS Beacon eNewsletter and MS educational events
|
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- CAR T-cell deaths in subjects with autoimmunity
- Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
- Brain scans link gray matter damage to MS disability worsening
- Press Release: BIG News from MS Views and News!
- Let’s listen to a potential way of Protecting the Myelin Sheath from Demyelination
- Image showing CT Brain Anatomy
- MS explained – Using the Pool Model, by Aaron Boster, MD
- How to Prevent Falls When You Have MS
- What’s the Connection Between MS and Seizures?
- Can Vitamin D Help Manage MS?
- Dysphagia – What causes it and how treated?
- Coping with Sudden MS Sweating When It’s Cold
- Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
- Comprehensive Guide to Bladder Dysfunction in MS
- The Surprising Side Effect She Didn’t Dare Talk About
- Incidentalomas in Multiple Sclerosis
- How to Treat MS Pain
- Wheelchair Fit for Function and Support
- Scientists Find New Evidence Linking Epstein-Barr Virus to MS
- MS Study Alert: How Can We Prevent Falls in People Who Use Wheelchairs? Researchers Recruiting for Two Studies
